UK Markets closed


Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
53.47-0.09 (-0.17%)
As of 8:18AM CEST. Market open.
Full screen
Previous close53.56
Bid0.00 x
Ask0.00 x
Day's range53.47 - 53.47
52-week range53.47 - 62.76
Avg. volume0
Market capN/A
PE ratio (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • 24/7 Wall St.6 hours ago

    Major Pharma Short Interest Takes a Big Step Back

    The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.

  • Forbes12 hours ago

    The Startling History Behind Merck's New Cancer Blockbuster

    The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.

  • Reuters2 days ago

    Merck immunotherapy fails to improve survival in head and neck cancer

    Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.